Cargando…
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
PURPOSE: Radium Ra 223 dichloride (radium-223, Xofigo®) is the first targeted alpha therapy for patients with castration-resistant prostate cancer and symptomatic bone metastases. Radium-223 provides a new treatment option for this setting, but also necessitates a new treatment management approach....
Autores principales: | Du, Yong, Carrio, Ignasi, De Vincentis, Giuseppe, Fanti, Stefano, Ilhan, Harun, Mommsen, Caroline, Nitzsche, Egbert, Sundram, Francis, Vogel, Wouter, Oyen, Wim, Lewington, Val |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537325/ https://www.ncbi.nlm.nih.gov/pubmed/28631036 http://dx.doi.org/10.1007/s00259-017-3756-7 |
Ejemplares similares
-
Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
por: van der Zande, Kim, et al.
Publicado: (2021) -
Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014) -
Radium-223 for the treatment of castration-resistant prostate cancer
por: El-Amm, Joelle, et al.
Publicado: (2015) -
Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
por: Prelaj, Arsela, et al.
Publicado: (2019) -
Patient selection and treatment response assessment in radium-223 therapy
por: Kay, M, et al.
Publicado: (2015)